The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
9MW2821, a novel Nectin-4 antibody-drug conjugate (ADC), combined with toripalimab in treatment-naïve patients with locally advanced or metastatic urothelial carcinoma (la/mUC): Results from a phase 1b/2 study.
 
Shusuan Jiang
No Relationships to Disclose
 
Hongqian Guo
No Relationships to Disclose
 
Hongchen Qu
No Relationships to Disclose
 
Yuchen Bai
No Relationships to Disclose
 
Benkang Shi
No Relationships to Disclose
 
Peng Zhang
No Relationships to Disclose
 
Xin Yao
No Relationships to Disclose
 
Tie Jun Yang
No Relationships to Disclose
 
Hang Huang
No Relationships to Disclose
 
Manming Cao
No Relationships to Disclose
 
Jun Guo
Consulting or Advisory Role - Bayer; MSD; Novartis; Oriengene; Pfizer; Roche; Shanghai Junshi BioSciences; Simcere
 
Xinan Sheng
Speakers' Bureau - Astellas Pharma; Junshi Pharmaceuticals; MSD Oncology; Pfizer; RemeGen
 
Jingming Dong
No Relationships to Disclose
 
Peipei Wang
No Relationships to Disclose
 
Shuhai Wang
No Relationships to Disclose